(Alliance News) - Genedrive PLC on Friday said draft guidance from the UK's National Institute for Health & Care Excellence has recommended that CYP2C19 genotyping should be used to manage ischemic stroke patients.
Genedrive shares rose 14% to 23.38 pence each in London on Friday morning.
The Manchester, England-based point-of-care molecular diagnostics company said that systematic reviews of the clinical and economic impact of genetic testing by the NICE diagnostics assessment centre indicated that CYP2C19 testing strategies "are likely to save costs and increase life expectancy compared with no testing".
"Screening patients to assess their clopidogrel resistance status allows for alternative treatments and better clinical outcomes," the company said.
Given that the CYP2C19 ID test is still in development, the NICE Committee considered its predicted performance and pricing in its models. Genedrive added that it expects to receive UKCA marking of the test before the publication of NICE's final report, which is scheduled for October.
Chief Executive David Budd said: "This is the second time we have had the opportunity to work with NICE on recommendations for pharmacogenetic testing, and I am pleased that they are very much in-line and supportive of our strategy in point of care pharmacogenomics for emergency care. The company remains focused on achieving release and UKCA approval of the Genedrive CYP2C19 ID Kit in advance of the final NICE guidance publication date."
By Harvey Dorset, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Genedrive (GDR)